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LETTERS TO THE EDITOR 
The Educational Role of 
Thrombolytic Therapy 
The recent article by Gorlin (I) on the present status of thrombolytic 
therapy in acute myocardial infarction needs further comments. I 
agree wholeheartedly with Gorlin when he concludes that “a small 
overall gain has been made with thrombolysis, which can benefit a 
small subset of patients with acute myocardial infarction, provided 
that both the immediate and the long-term risks are carefully 
assessed.” In most instances thrombolytic therapy is failure- 
expensive medicine. If one accepts the laboratory data that 85% of 
heart muscle death takes place within the first 2 h, it appears to be 
almost impossible to give effective thrombolytic therapy within that 
short time range. The average time the patient has prolonged chest 
pain before hospital arrival is approximately I .5 h. In the emergency 
room, there is still significant delay [mean about 1.5 h (2)]. Even 
when thrombolytic therapy is given, there is another 45 min before 
the vessel is open. Therefore. most patients appear to get the drug 
too late. 
What Gorlin does not take into account is that the benefits of 
thrombolytic therapy may not be in the treatment of patients with 
myocardial infarction but in the publicity given to early care of the 
patient with ischemic disease. The awareness program for early 
intervention will bring into the hospital setting many patients with 
unstable angina, and this is what will be most important in the long 
run. 
The Paul Dudley White Coronary Care System at Saint Agnes 
Hospital (3) has had a chest pain emergency room for the last 8 years 
and has provided early cardiac care with an educational program 
aggressively given within its community. This early cardiac care 
approach has increased the number of admissions from 1,000 to 
2,000 during this period of time and has changed the subsets so that 
the proportion of patients with unstable angina is now within the 
60% range. 
The emphasis on early cardiac care may help reduce the time 
frames for treatment of acute myocardial infarction, but in most 
cases it will be expensive medicine given too late. Perhaps para- 
medic administration of therapy or fast tracks by medical residents 
within hospitals may improve this picture. but in most cases 
significant damage has been done. The “Golden Fleece,” namely 
the patient with unstable angina. may be a by-product of this 
enthusiasm for thrombolytic therapy and may provide us with an 
enhanced delivery system for patients seen before the occurrence of 
cardiac damage and sudden death. In this setting. an educational 
program for chest pain awareness similar to the present program5 
for hypertension, cigarette smoking and cholesterol could procide 
us with an excellent tool for significantly reducing mortality and 
morbidity. To do so, all 6.700 hospitals in the United State5 mu>t 
provide this link-up between the community and early cardiac care. 
It is my viewpoint that Gorlin (I) may have missed the mark by 
not appreciating a more panoramic view of what thrombolytic 
therapy can mean in the long run. 
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Reply 
I appreciate very much the comments expressed by Bahr reminding 
all of us that patients must get to hospital sooner if improvements 
are to be made in the rate of survival. Thrombolytic therapy is only 
one of a number of proposals for early therapy that have been made 
over the years. Bahr may recall that Pantridge and Geddes (I) in 
Belfast directed attention to the number of patients who might be 
salvageable if seen within minutes of the inception of a myocardial 
infarction. So it was that Sarnoff (2) proposed the development of 
early electrocardiographic alert systems, including prepackaged 
antidotes for arrhythmias. So it was that the community-wide 
Nottingham study (3) tested the difference in the outcome of patients 
rushed to the hospital versus those treated at home by physicians. 
Thus the concept of seeing the patient earlier and earlier, at a point 
where one can intervene appropriately, is not new and is as unlikely 
to be a by-product of thrombolytic therapy any more than it was of 
antiarrhythmic and defibrillating therapy in an earlier generation. 
Bahr makes a good point in that the public needs to be educated, 
but education is only the first step. Aspects of patient behavior such 
as denial, nonspecific symptomatology and the confounding compo- 
nent of hyporesponsiveness of patients to their complaints all play a 
part in delaying therapy. 
It is worth examining why we are seeing more patients with 
so-called unstable angina than frank Q wave myocardial infarction. 
This trend predates thrombolytic therapy. It almost suggests that an 
alteration has occurred in the atheromatous plaque and its depth or 
extent or rupture, leading to a less catastrophic or complete arterial 
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